$JNJ
Johnson & Johnson · NYSE · Healthcare
- Market cap
- 635.07B
- Volume
- 5.31M
- P/E
- 40.03
- Day range
- 262.40 – 266.02
- 52w range
- 184.66 – 281.07
- Analyst target
- 279.41
AI Summary
Generating a unique summary for JNJ…
AI-generated for information only — not investment advice.
Share this ticker
$JNJ -1.42% at 263.81 Ray Dalio and 1 other tracked billionaires hold it. $NTRA $LLY $BHC https://billionairestrading.com/stocks/JNJ
Company summary
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Institutional ownership
Institutions hold 76.83% · insiders 0.05% · 5,830 institutions
| Holder | Shares | Value | % held | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 212.10M | $55.95B | 8.81% | 2026-06-30 |
| Vanguard Capital Management LLC | 157.23M | $41.48B | 6.53% | 2026-06-30 |
| State Street Corporation | 133.78M | $35.29B | 5.56% | 2026-06-30 |
| Vanguard Portfolio Management LLC | 64.37M | $16.98B | 2.67% | 2026-06-30 |
| Geode Capital Management, LLC | 59.09M | $15.59B | 2.45% | 2026-06-30 |
| JPMORGAN CHASE & CO | 58.30M | $15.38B | 2.42% | 2026-06-30 |
| Morgan Stanley | 44.81M | $11.82B | 1.86% | 2026-06-30 |
| NORGES BANK | 31.83M | $8.40B | 1.32% | 2026-06-30 |
| State Farm Mutual Automobile Insurance Co | 31.59M | $8.33B | 1.31% | 2026-06-30 |
| Northern Trust Corporation | 28.79M | $7.60B | 1.20% | 2026-06-30 |
Hedge fund & billionaire activity
Insider transactions
| Insider | Role | Transaction | Shares | Date |
|---|---|---|---|---|
| SCHMID TIMOTHY | Officer | Conversion of Exercise of derivative security at price 131.94 - 151.41 per share. | 33.6K | 2026-09-02 |
| SCHMID TIMOTHY | Officer | Sale at price 274.74 per share. | 33.6K | 2026-09-02 |
| TAUBERT JENNIFER L | Officer | Conversion of Exercise of derivative security at price 115.67 per share. | 15.0K | 2026-08-17 |
| TAUBERT JENNIFER L | Officer | Sale at price 263.36 per share. | 15.0K | 2026-08-17 |
| DUATO JOAQUIN BOIX | Chief Executive Officer | Conversion of Exercise of derivative security at price 115.67 per share. | 123.3K | 2026-08-13 |
| DUATO JOAQUIN BOIX | Chief Executive Officer | Sale at price 261.00 - 262.00 per share. | 123.3K | 2026-08-13 |
| FORMINARD ELIZABETH | Officer | Conversion of Exercise of derivative security at price 131.94 per share. | 9.3K | 2026-08-06 |
| FORMINARD ELIZABETH | Officer | Sale at price 255.93 - 257.76 per share. | 15.9K | 2026-08-06 |
| DUATO JOAQUIN BOIX | Chief Executive Officer | Sale at price 258.06 - 258.74 per share. | 48.5K | 2026-08-05 |
| BROADHURST VANESSA | Officer | Conversion of Exercise of derivative security at price 129.51 - 131.94 per share. | 23.1K | 2026-07-20 |
| BROADHURST VANESSA | Officer | Sale at price 251.27 per share. | 23.1K | 2026-07-20 |
| WENGEL KATHRYN E | Chief Technology Officer | Conversion of Exercise of derivative security at price 115.67 per share. | 10.0K | 2026-06-11 |
Analyst ratings
Consensus score 1.91 (1 = strong buy, 5 = sell) · mean target 279.41
- Wells FargoOverweightmain2026-10-16
- Morgan StanleyOverweightmain2026-10-15
- Leerink PartnersOutperformmain2026-10-14
- Wells FargoOverweightmain2026-10-14
- RBC CapitalOutperformmain2026-10-14
- GuggenheimBuyreit2026-10-07
- RBC CapitalOutperformmain2026-10-06
- CitigroupBuymain2026-10-05
- JP MorganNeutralmain2026-09-29
- HSBCBuymain2026-09-10
Earnings
Next report: 2026-10-13
| Quarter | EPS actual | EPS estimate | Surprise |
|---|---|---|---|
| 4Q2025 | 2.46 | 2.46 | -0.00 |
| 1Q2026 | 2.70 | 2.68 | 0.02 |
| 2Q2026 | 2.90 | 2.85 | 0.05 |
| 3Q2026 | 2.59 | 2.52 | 0.07 |
SEC filings
- 10-QPeriodic Financial Reports2026-10-21Open
- 8-KCorporate Changes & Voting Matters2026-10-13Open
- N-PXAnnual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX2026-08-11Open
- 8-KCorporate Changes & Voting Matters2026-08-04Open
- 8-KCorporate Changes & Voting Matters2026-07-29Open
- 8-KCorporate Changes & Voting Matters2026-07-28Open
- 10-QPeriodic Financial Reports2026-07-23Open
- 8-KCorporate Changes & Voting Matters2026-07-15Open
- 11-KAnnual report of employee stock purchase2026-06-25Open
- SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-27Open
Latest JNJ news
- Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?
Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.
Sat, 24 Oct 2026 16:31:01 +0000
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localized or locally advanced prostate cancer. The apalutamide plus ADT regimen reduced the risk of disease recurrence or death by 62 percent compared with surgery alone. The regimen also showed a n
Sat, 24 Oct 2026 09:30:00 +0000
- J&J’s Smith & Nephew Deal Collapsed Over One Executive. Here’s What It Means for the DePuy Spin
Johnson & Johnson (JNJ:NYSE) shares closed down 1. 42% at $263.
Sat, 24 Oct 2026 07:38:13 +0000
- Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index dropping 1.3% and
Fri, 23 Oct 2026 19:56:25 +0000
- Sector Update: Healthcare Stocks Decline Friday Afternoon
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index dropping 1.2% and the
Fri, 23 Oct 2026 17:51:34 +0000
- Smith And Nephew Merger Talks With Johnson & Johnson Collapse Over Leadership Dispute
Key Stats for Johnson & Johnson StockPrice change for Johnson & Johnson stock in last 6 months: 14%$JNJ Stock Price as of Oct. 22: $26752-Week High: $281$JNJ Stock Price Target: $279__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__>>> What Happened?Smith & Nephew held merger talks with Johnson & Johnson (JNJ:NYSE) to combine with J&J’s orthopedics division.
Fri, 23 Oct 2026 17:06:59 +0000
- Correction: Update: Market Chatter: Johnson & Johnson Orthopedics, Smith & Nephew Merger Collapsed Over Leadership Dispute
(Corrects to clarify that Smith & Nephew declined to comment and updates the second paragraph with m
Fri, 23 Oct 2026 14:41:57 +0000
- Johnson & Johnson (JNJ) Stock Gets Fair Value Bump On Mixed Analyst Target Changes
Johnson & Johnson’s implied fair value has been adjusted from US$270.59 to US$279.41 per share, reflecting a modest reset in price targets around the stock. Recent research shows a split view, with more positive analysts pointing to earnings resilience and the drug pipeline, while cautious voices highlight valuation, MedTech execution risk, and potential earnings dilution from recent deals. In the sections that follow, you will see how these shifting targets and narratives fit together and...
Fri, 23 Oct 2026 14:13:29 +0000